Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
gilead sciences
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
abbvie
astrazeneca
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
covid-19
deals
detroit blog main
detroit top stories
europe blog main
europe top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
startups
takeda pharmaceutical
texas blog main
texas top stories
unity biotechnology
wisconsin blog main
wisconsin top stories
akouos
What
gilead
4
×
sciences
4
×
ceo
drug
acquisitions
bio
covid
daniel
o’day
pipeline
roundup
adding
addressed
announced
answers
bets
big
biggest
boost
build
buy
cancer
collabs
company’s
cost
deal
debut
dyne’s
early
expensive
far
gilead’s
hasten
help
indicated
introduce
ipo
medicine
medicines
microbiome
Language
unset
Current search:
sciences
×
gilead
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@slashgear.com
4 years ago
Gilead CEO answers big COVID-19 question: How much will remdesivir cost
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango